{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:21:43Z","timestamp":1790144503823,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MRC-UKRI","award":["MR\/W014491\/1"],"award-info":[{"award-number":["MR\/W014491\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Multimorbidity has been identified as a research priority in recent years; fibrosis (progressive organ scarring) is one mechanism that may underpin multimorbidity. Some studies suggest hypertension could be fibrotic, particularly severe hypertension (uncontrollable with medications); however, it is not currently known whether severe hypertension is associated with fibrotic conditions. The objective is to investigate whether treatment-resistant hypertension is associated with fibrotic conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We used the Clinical Practice Research Datalink Aurum primary care database to define a cohort of people with hypertension during 2015. We determined the percentage of people who had conditions with fibrotic manifestations and explored differences respective to hypertension control. We applied multivariable logistic regression to analyse associations (P &amp;lt; 0.001) between hypertension control and each fibrotic condition, respectively. Of 1 340 495 people with hypertension during 2015, 83.50% (n = 1 119 333) had managed hypertension either by lifestyle or by medication; 16.50% (n = 221 162) had treatment-resistant hypertension. Fibrotic conditions were more common {75.40% [95% confidence interval (CI): 75.20\u201375.60] vs. 68.90% (95% CI: 68.81\u201370.01)} in people with treatment-resistant hypertension compared with those with managed hypertension. We found that treatment-resistant hypertension was associated with cardiomyopathy (ORadj: 1.85, 95% CI: 1.81\u20131.90), both Type 1 and Type 2 diabetes (ORadj: 1.49, 95% CI: 1.44\u20131.55, ORadj: 1.61, 95% CI: 1.60\u20131.63, respectively), liver fibrosis (ORadj: 1.52, 95% CI: 1.46\u20131.58), valve fibrosis (ORadj: 1.41, 95% CI: 1.37\u20131.44), and urinary fibrosis (ORadj: 1.41, 95% CI: 1.36\u20131.47).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The proportion of people with fibrotic conditions was greater in those with treatment-resistant hypertension than managed hypertension. The identified associations between treatment-resistant hypertension and fibrotic conditions may point to common disease pathways, which should be further explored to understand shared mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf068","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T15:21:45Z","timestamp":1739287305000},"page":"1227-1235","source":"Crossref","is-referenced-by-count":2,"title":["The association between fibrotic diseases and treatment-resistant hypertension in England"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4355-6546","authenticated-orcid":false,"given":"Georgie M","family":"Massen","sequence":"first","affiliation":[{"name":"School of Public Health, Imperial College London , 86 Wood Lane, London SW7 2AZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W","family":"Stone","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London , 86 Wood Lane, London SW7 2AZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Gisli","family":"Jenkins","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Leicester , Leicester ,","place":["UK"]},{"name":"NIHR Biomedical Research Centre, University of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise V","family":"Wain","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Leicester , Leicester ,","place":["UK"]},{"name":"NIHR Biomedical Research Centre, University of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Stewart","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upasana","family":"Tayal","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-4869","authenticated-orcid":false,"given":"Jennifer K","family":"Quint","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London , 86 Wood Lane, London SW7 2AZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2026051513422534900_zwaf068-B1","author":"NHS Digital"},{"key":"2026051513422534900_zwaf068-B2","author":"CDC (Centers for Disease Control and Prevention)"},{"key":"2026051513422534900_zwaf068-B3","author":"NICE"},{"key":"2026051513422534900_zwaf068-B4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/heartjnl-2011-300741","article-title":"Resistant hypertension","volume":"98","author":"Fagard","year":"2012","journal-title":"Heart"},{"key":"2026051513422534900_zwaf068-B5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.amjms.2016.03.004","article-title":"The association between multimorbidity and quality of life, health status and functional disability","volume":"352","author":"Williams","year":"2016","journal-title":"Am J Med Sci"},{"key":"2026051513422534900_zwaf068-B6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.archger.2016.07.008","article-title":"Multimorbidity and mortality in older adults: a systematic review and meta-analysis","volume":"67","author":"Nunes","year":"2016","journal-title":"Arch Gerontol Geriatr"},{"key":"2026051513422534900_zwaf068-B7","doi-asserted-by":"crossref","first-page":"2235042X18804063","DOI":"10.1177\/2235042X18804063","article-title":"Multimorbidity and mortality","volume":"8","author":"Willadsen","year":"2018","journal-title":"J Comorb"},{"key":"2026051513422534900_zwaf068-B8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12877-020-1425-3","article-title":"Associations between complex multimorbidity, activities of daily living and mortality among older Norwegians. A prospective cohort study: the HUNT study, Norway","volume":"20","author":"Storeng","year":"2020","journal-title":"BMC Geriatr"},{"key":"2026051513422534900_zwaf068-B9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12916-019-1305-x","article-title":"Relationship between multimorbidity, demographic factors and mortality: findings from the UK biobank cohort","volume":"17","author":"Jani","year":"2019","journal-title":"BMC Med"},{"key":"2026051513422534900_zwaf068-B10","author":"The Academy of Medical Sciences"},{"key":"2026051513422534900_zwaf068-B11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/geriatrics5040085","article-title":"Multi-morbidity and polypharmacy in older people: challenges and opportunities for clinical practice","volume":"5","author":"Aggarwal","year":"2020","journal-title":"Geriatrics"},{"key":"2026051513422534900_zwaf068-B12","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(18)30941-3","article-title":"Making more of multimorbidity: an emerging priority","volume":"391","author":"The Lancet","year":"2018","journal-title":"The Lancet"},{"key":"2026051513422534900_zwaf068-B13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.14336\/AD.2018.0601","article-title":"The role of pathological aging in cardiac and pulmonary fibrosis","volume":"10","author":"Murtha","year":"2019","journal-title":"Aging Dis"},{"key":"2026051513422534900_zwaf068-B14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1172\/JCI93563","article-title":"Resolution of organ fibrosis","volume":"128","author":"Jun","year":"2018","journal-title":"J Clin Invest"},{"key":"2026051513422534900_zwaf068-B15","doi-asserted-by":"crossref","first-page":"101393","DOI":"10.1016\/j.arr.2021.101393","article-title":"Fibroageing: an ageing pathological feature driven by dysregulated extracellular matrix-cell mechanobiology","volume":"70","author":"Selman","year":"2021","journal-title":"Ageing Res Rev"},{"key":"2026051513422534900_zwaf068-B16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J Pathol"},{"key":"2026051513422534900_zwaf068-B17","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1073\/pnas.1621375114","article-title":"Unifying mechanism for different fibrotic diseases","volume":"114","author":"Wernig","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051513422534900_zwaf068-B18","author":"World Health Organization"},{"key":"2026051513422534900_zwaf068-B19","doi-asserted-by":"crossref","first-page":"101860","DOI":"10.1016\/j.eclinm.2023.101860","article-title":"Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis","volume":"57","author":"Chowdhury","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2026051513422534900_zwaf068-B20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/qjmed\/hcad050","article-title":"Classifying the unclassifiable\u2014a Delphi study to reach consensus on the fibrotic nature of diseases","volume":"116","author":"Massen","year":"2023","journal-title":"QJM Int J Med"},{"key":"2026051513422534900_zwaf068-B21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/CLEP.S463499","article-title":"Using routinely collected electronic healthcare record data to investigate fibrotic multimorbidity in England","volume":"16","author":"Massen","year":"2024","journal-title":"Clin Epidemiol"},{"key":"2026051513422534900_zwaf068-B22","first-page":"151","article-title":"UK electronic healthcare records for research: a scientometric analysis of respiratory, cardiovascular, and COVID-19 publications","volume":"15","author":"Massen","year":"2024","journal-title":"Pragmat Obs Res"},{"key":"2026051513422534900_zwaf068-B23","doi-asserted-by":"publisher","author":"Clinical Practice Research Datalink","DOI":"10.48329\/7njs-8a57"},{"key":"2026051513422534900_zwaf068-B24","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2026051513422534900_zwaf068-B25","doi-asserted-by":"crossref","first-page":"e002640","DOI":"10.1136\/openhrt-2024-002640","article-title":"Review of codelists used to define hypertension in electronic health records and development of a codelist for research","volume":"11","author":"Massen","year":"2024","journal-title":"Open Heart"},{"key":"2026051513422534900_zwaf068-B26","author":"World Health Organization"},{"key":"2026051513422534900_zwaf068-B27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2026051513422534900_zwaf068-B28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","article-title":"Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants","volume":"389","author":"Zhou","year":"2017","journal-title":"Lancet"},{"key":"2026051513422534900_zwaf068-B29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"2026051513422534900_zwaf068-B30","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurjpc\/zwad066","article-title":"Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry","volume":"30","author":"Ebinger","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026051513422534900_zwaf068-B31","author":"Hypertension"},{"key":"2026051513422534900_zwaf068-B32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/HYPERTENSIONAHA.117.08314","article-title":"Hypertensive kidney injury and the progression of chronic kidney disease","volume":"70","author":"Griffin","year":"2017","journal-title":"Hypertension"},{"key":"2026051513422534900_zwaf068-B33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/jhh.2013.55","article-title":"Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage","volume":"28","author":"Mennuni","year":"2014","journal-title":"J Hum Hypertens"},{"key":"2026051513422534900_zwaf068-B34","first-page":"327","article-title":"Resistant hypertension in type 2 diabetes: prevalence and patients characteristics","volume":"88","author":"Ciobanu","year":"2015","journal-title":"Clujul Med"},{"key":"2026051513422534900_zwaf068-B35","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3390\/jcm11051455","article-title":"Rethinking resistant hypertension","volume":"11","author":"Bourque","year":"2022","journal-title":"J Clin Med"},{"key":"2026051513422534900_zwaf068-B36","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3390\/biomedicines12081802","article-title":"mTOR dysregulation, insulin resistance, and hypertension","volume":"12","author":"Stanciu","year":"2024","journal-title":"Biomedicines"},{"key":"2026051513422534900_zwaf068-B37","doi-asserted-by":"crossref","first-page":"200269","DOI":"10.1183\/16000617.0269-2020","article-title":"The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis","volume":"29","author":"Plat\u00e9","year":"2020","journal-title":"Eur Respir Rev"},{"key":"2026051513422534900_zwaf068-B38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1524-6175.2007.06626.x","article-title":"Mechanisms of cardiac fibrosis in hypertension","volume":"9","author":"D\u00edez","year":"2007","journal-title":"J Clin Hypertens"},{"key":"2026051513422534900_zwaf068-B39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/01.HYP.0000118584.33350.7d","article-title":"Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?","volume":"43","author":"Kuwahara","year":"2004","journal-title":"Hypertension"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf068\/61865748\/zwaf068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/7\/1227\/61865748\/zwaf068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/7\/1227\/61865748\/zwaf068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:42:35Z","timestamp":1778866955000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/7\/1227\/8010907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,2,13]]},"published-print":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf068","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,2,13]]}}}